Antiemetic Regimen with Aprepitant in the Prevention of Chemotherapy-induced Nausea and Vomiting: An Updated Systematic Review and Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2020 Sep 3

PMID 32872006

Citations 3

Authors

Tingting Qiu

Peng Men

Xiaohan Xu

Suodi Zhai

Xiangli Cui

Affiliations

Soon will be listed here.

Abstract

Objective: To systematically evaluate the efficacy and safety of antiemetic regimen with aprepitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) and provide updated information for clinical practice.

Methods: Pubmed, Embase, the Cochrane Library, and 3 Chinese literature databases were systematically searched. Randomized controlled trials comparing standard regimen (5-hydroxytryptamine-3 receptor antagonist and glucocorticoid) with aprepitant triple regimen (aprepitant plus the standard regimen) for preventing CINV were screened. Literature selection, data extraction, and quality evaluation were performed by 2 reviewers independently. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated in the meta-analysis using RevMan 5.3 software.

Results: A total of 51 randomized controlled trials were finally included in the systematic review. Compared with the standard regimen, the aprepitant triple regimen significantly improved the complete response in the overall (OR 1.88, 95% CI 1.71-2.07), acute (OR 1.96, 95% CI 1.65-2.32) and delayed (OR 1.96, 95% CI 1.70-2.27) phases, regardless of emetogenic risk of chemotherapy. Aprepitant could also significantly enhance the proportions of patients who have no emesis, nausea, or use of rescue medication respectively in the overall, acute and/or delayed phases. Aprepitant was found to be associated with decreased risk of constipation (OR 0.85, 95% CI 0.74-0.97), but increased the incidence of hiccup (OR 1.26, 95% CI 1.05, 1.51). There were no statistically significant differences between the 2 groups on other safety outcomes.

Conclusion: The aprepitant triple regimen is effective for the prevention of CINV in patients being treated with moderately or highly emetogenic chemotherapy, and has a significant tendency to reduce the risk of constipation and increase the incidence of hiccup.

Citing Articles

Efficacy and safety of Aprepitant-containing triple therapy for the prevention and treatment of chemotherapy-induced nausea and vomiting: A meta-analysis.

Zhang M, Guo Q, Zhang T, Fu M, Bi H, Zhang J Medicine (Baltimore). 2023; 102(47):e35952.

PMID: 38013306 PMC: 10681589. DOI: 10.1097/MD.0000000000035952.

Electrochemotherapy: An Alternative Strategy for Improving Therapy in Drug-Resistant SOLID Tumors.

Condello M, DAvack G, Spugnini E, Meschini S Cancers (Basel). 2022; 14(17).

PMID: 36077875 PMC: 9454613. DOI: 10.3390/cancers14174341.

Complementary and alternative medicine modalities used to treat adverse effects of anti-cancer treatment among children and young adults: a systematic review and meta-analysis of randomized controlled trials.

Mora D, Overvag G, Jong M, Kristoffersen A, Stavleu D, Liu J BMC Complement Med Ther. 2022; 22(1):97.

PMID: 35366871 PMC: 8976304. DOI: 10.1186/s12906-022-03537-w.

References

Svanberg A, Birgegard G . Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting. Oncology. 2015; 89(1):31-6. DOI: 10.1159/000371523. View

Schmoll H, Aapro M, Poli-Bigelli S, Kim H, Park K, Jordan K . Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006; 17(6):1000-6. DOI: 10.1093/annonc/mdl019. View

Hesketh P, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I . Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014; 25(7):1340-1346. PMC: 4071755. DOI: 10.1093/annonc/mdu110. View

Asano H, Watanabe M, Kawaguchi A, Yanae M, Funakami Y, Wada T . [A search for the risk factors for hiccups and evaluation of antiemetic therapy in CDDP-based chemotherapy, using cluster analysis]. Gan To Kagaku Ryoho. 2013; 40(8):1031-6. View

Poli-Bigelli S, Rodrigues-Pereira J, Carides A, Ma G, Eldridge K, Hipple A . Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003; 97(12):3090-8. DOI: 10.1002/cncr.11433. View

Hesketh P, Bohlke K, Lyman G, Basch E, Chesney M, Clark-Snow R . Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J Clin Oncol. 2015; 34(4):381-6. DOI: 10.1200/JCO.2015.64.3635. View

Nasu R, Nannya Y, Kurokawa M . A randomized controlled study evaluating the efficacy of aprepitant for highly/moderately emetogenic chemotherapies in hematological malignancies. Int J Hematol. 2015; 101(4):376-85. DOI: 10.1007/s12185-015-1735-y. View

Navari R . Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents. Drugs. 2013; 73(3):249-62. DOI: 10.1007/s40265-013-0019-1. View

Kusagaya H, Inui N, Karayama M, Fujisawa T, Enomoto N, Kuroishi S . Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer. Lung Cancer. 2016; 90(3):410-6. DOI: 10.1016/j.lungcan.2015.11.009. View

10.

Kaushal P, Atri R, Soni A, Kaushal V . Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients. Ecancermedicalscience. 2015; 9:567. PMC: 4583242. DOI: 10.3332/ecancer.2015.567. View

11.

Aridome K, Mori S, Baba K, Yanagi M, Hamanoue M, Miyazono F . A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients. Mol Clin Oncol. 2016; 4(3):393-398. PMC: 4774568. DOI: 10.3892/mco.2015.724. View

12.

Chawla S, Grunberg S, Gralla R, Hesketh P, Rittenberg C, Elmer M . Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer. 2003; 97(9):2290-300. DOI: 10.1002/cncr.11320. View

13.

Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla R, Bruera E . 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016; 27(suppl 5):v119-v133. DOI: 10.1093/annonc/mdw270. View

14.

Di Maio M, Baratelli C, Bironzo P, Vignani F, Bria E, Sperti E . Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018; 124:21-28. DOI: 10.1016/j.critrevonc.2018.02.001. View

15.

Navari R, Reinhardt R, Gralla R, Kris M, Hesketh P, Khojasteh A . Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med. 1999; 340(3):190-5. DOI: 10.1056/NEJM199901213400304. View

16.

Abdel-Rahman O . Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysis. Ther Adv Med Oncol. 2016; 8(5):396-406. PMC: 4981292. DOI: 10.1177/1758834016654902. View

17.

Rapoport B, Jordan K, Boice J, Taylor A, Brown C, Hardwick J . Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2009; 18(4):423-31. DOI: 10.1007/s00520-009-0680-9. View

18.

Warr D, Street J, Carides A . Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer. 2010; 19(6):807-13. DOI: 10.1007/s00520-010-0899-5. View

19.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

20.

de Wit R, Herrstedt J, Rapoport B, Carides A, Carides G, Elmer M . Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol. 2003; 21(22):4105-11. DOI: 10.1200/JCO.2003.10.128. View